Lilly sues two medical spas over copycat weight-loss drugs
Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound. The new lawsuits name Thrive Health and Wellness LLC and Valhalla Vitality LLC.
Eli Lilly’s stock falls as weight-loss drug sales disappoint
Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its weight-loss drugs.
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.
Ozempic 3.0? This drug causes the greatest weight loss — by far
Ozempic 3.0? Retatrutide — an experimental drug nicknamed “triple G” — could be your best shot at a slimmer waistline when it becomes available to the public, a Monday study found. Obese adults who took the weekly injection lost up to 22% of their starting weight after 11 months — compared to just 14% over 15 months for semaglutide,
Lilly asks to join lawsuit over compounded versions of its weight-loss drugs
Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug Administration over the agency's decision that Lilly's blockbuster weight-loss and diabetes drugs are no longer in short supply.
Eli Lilly CEO expects new weight loss pill to be approved next year
Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.
Eli Lilly was hoping weight loss drug demand would be even bigger
Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its popular weight-loss drugs, Zepbound and Mounjaro.
Lilly forecasts weak sales of weight-loss drug in fourth quarter
Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street expectations in the fourth quarter, but forecast 2025 revenue largely above estimates.
Some GLP-1s Achieve More Weight Loss Than Others: Study
However, a third drug also FDA-approved for weight loss, liraglutide (Saxenda), didn’t work as well as the others, ...
Healio17h
Top in endocrinology: Novel GLP-1 lowers weight; osteoporosis detection with CT plus AI
Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according ...
Miami Herald10d
Ask a Health Professional: How do semaglutide and tirzepatide support wellness goals?
Medications like semaglutide and tirzepatide have gained significant attention for their impressive weight-loss effects, but they do much more than just helping you shed pounds. Let’s dive into ...
krcgtv.com6d
Weight loss options to help New Year's resolutions include GLP-1 injections
The New Year is a time of reflection and change for many Americans, who start each January with a clean slate and goals for ...
FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?
The U.S. Food and Drug Administration (FDA) recently approved Zepbound® (tirzepatide) as the first prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with ...
Can this viral 'Natural Mounjaro' drink help in weight loss? Here's what to know
Viral TikTok alternatives like Natural Mounjaro, Oatzempic, and Tadpole water claim to aid weight loss by curbing appetite ...